Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Here is the whole quote with 2 additional reports.

"Based on an interim analysis of data from the phase 2, dose-finding portion (Part 1) of 2 ongoing phase 2/3 trials evaluating molnupiravir, Merck and Ridgeback Biotherapeutics have decided to halt the MOVe-IN study for hospitalized COVID-19 patients and proceed with the phase 3 portion (Part 2) of the MOVe-OUT study in outpatients with COVID-19"

https://www.empr.com/home/news/molnupiravir-merck-ridgeback-oral-antiviral-investigational-covid-19-treatment/

The pill known as molnupiravir reduced virus levels in patients during a mid-stage study but didn’t show a meaningful benefit in preventing hospitalizations and deaths, the Kenilworth, New Jersey-based company said in a statement. It decided to discontinue its development for the sickest patients, those hospitalized with the infection, after the trial showed it was unlikely to help them.

https://www.bloomberg.com/news/articles/2021-04-15/merck-setback-limits-study-of-covid-pill-to-treat-milder-disease

Merck MRK 8.37% & Co. and its partner Ridgeback Biotherapeutics LP said they are stopping a trial of their experimental Covid-19 drug after it failed to help hospitalized patients, delivering another setback to doctors seeking treatments to use for the disease.

https://www.wsj.com/articles/merck-partner-halt-covid-19-treatment-trial-for-hospitalized-patients-11618483561

This portion of the quote is incorrect.

...after the FDA asked for additional information.

Merck released the stories about MK7110 the oncoimmune anti-inflammatory drug and EIDD-2810 about the same time and the announcements were in the same articles.

Thanks for the correction.

Farrell